News >

FDA Approves Higher-Dose Tablet of Brigatinib for NSCLC

Jason M. Broderick @jasoncology
Published: Tuesday, Oct 03, 2017

The FDA has approved a supplemental new drug application for the use of 180-mg tablets of brigatinib (Alunbrig) for the treatment of patients with non–small cell lung cancer (NSCLC).

Takeda, the manufacturer of brigatinib, reported in a press release that updated data from the ALTA trial will be presented at the 18th World Conference on Lung Cancer, being held October 15 to 18 in Yokohama, Japan.
Kim D-W, Tiseo M, Ahn M-J, et al. Brigatinib (BRG) in patients (pts) with crizotinib (CRZ)-refractory ALK+ non-small cell lung cancer (NSCLC): First report of efficacy and safety from a pivotal randomized phase (ph) 2 trial (ALTA). J Clin Oncol. 2016;34 (suppl; abstr 9007).

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 2nd Annual School of Nursing Oncology™Sep 28, 20191.5
Medical Crossfire®: Experts Weigh-In on Emerging Immune Checkpoint Inhibitors and Combination Strategies for Advanced NSCLCNov 30, 20191.5
Publication Bottom Border
Border Publication
x